Press Releases

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease

Posted on August 4, 2021

INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021

Posted on July 26, 2021

INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800

Posted on June 8, 2021

INOVIO to Present at the Jefferies 2021 Virtual Healthcare Conference

Posted on May 25, 2021

INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors

Posted on May 17, 2021

INOVIO’s Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

Posted on May 12, 2021

INOVIO Reports First Quarter 2021 Financial Results

Posted on May 10, 2021

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

Posted on May 10, 2021

INOVIO to Present at Upcoming Investor Conferences in May

Posted on May 4, 2021

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

Posted on April 27, 2021

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.